The flavonols quercetin and 3,4-dihydroxyflavonol reduce platelet function and delay thrombus formation in a model of type 1 diabetes

S. Mosawy, D.E. Jackson, O.L. Woodman, Matthew Linden

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Diabetes is associated with increased cardiovascular risk. We have recently shown that the naturally occurring flavonol quercetin (Que) or the synthetic flavonol 3,4-dihydroxyflavonol (DiOHF) inhibits platelet function and delays thrombus formation in healthy mice. Therefore, the aim of this study was to investigate the effect of Que or DiOHF treatment on platelet function and ferric chloride-induced carotid artery thrombosis in a mouse model of type 1 diabetes. Diabetic mice treated with Que or DiOHF maintained blood flow at a significantly higher level than untreated diabetic mice at the end of the recording period. In addition, treatment with Que or DiOHF significantly reduced diabetes-induced platelet hyper-aggregability in response to platelet agonist stimulation. Furthermore, treatment with Que or DiOHF significantly inhibited dense, but not alpha, granule exocytosis in diabetic and control mice. Our demonstration that flavonols delay thrombus formation in diabetes suggests a potential clinical role for these compounds in anti-platelet therapy. © The Author(s) 2014.
Original languageEnglish
Pages (from-to)174-181
JournalDiabetes and Vascular Disease Research
Volume11
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Flavonols
Quercetin
Type 1 Diabetes Mellitus
Thrombosis
Blood Platelets
Carotid Artery Thrombosis
Exocytosis

Cite this

@article{02102067f2bc41eb85290bd15ce0e503,
title = "The flavonols quercetin and 3,4-dihydroxyflavonol reduce platelet function and delay thrombus formation in a model of type 1 diabetes",
abstract = "Diabetes is associated with increased cardiovascular risk. We have recently shown that the naturally occurring flavonol quercetin (Que) or the synthetic flavonol 3,4-dihydroxyflavonol (DiOHF) inhibits platelet function and delays thrombus formation in healthy mice. Therefore, the aim of this study was to investigate the effect of Que or DiOHF treatment on platelet function and ferric chloride-induced carotid artery thrombosis in a mouse model of type 1 diabetes. Diabetic mice treated with Que or DiOHF maintained blood flow at a significantly higher level than untreated diabetic mice at the end of the recording period. In addition, treatment with Que or DiOHF significantly reduced diabetes-induced platelet hyper-aggregability in response to platelet agonist stimulation. Furthermore, treatment with Que or DiOHF significantly inhibited dense, but not alpha, granule exocytosis in diabetic and control mice. Our demonstration that flavonols delay thrombus formation in diabetes suggests a potential clinical role for these compounds in anti-platelet therapy. {\circledC} The Author(s) 2014.",
author = "S. Mosawy and D.E. Jackson and O.L. Woodman and Matthew Linden",
year = "2014",
doi = "10.1177/1479164114524234",
language = "English",
volume = "11",
pages = "174--181",
journal = "DIABETES & VASCULAR DISEASE RESEARCH",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "3",

}

The flavonols quercetin and 3,4-dihydroxyflavonol reduce platelet function and delay thrombus formation in a model of type 1 diabetes. / Mosawy, S.; Jackson, D.E.; Woodman, O.L.; Linden, Matthew.

In: Diabetes and Vascular Disease Research, Vol. 11, No. 3, 2014, p. 174-181.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The flavonols quercetin and 3,4-dihydroxyflavonol reduce platelet function and delay thrombus formation in a model of type 1 diabetes

AU - Mosawy, S.

AU - Jackson, D.E.

AU - Woodman, O.L.

AU - Linden, Matthew

PY - 2014

Y1 - 2014

N2 - Diabetes is associated with increased cardiovascular risk. We have recently shown that the naturally occurring flavonol quercetin (Que) or the synthetic flavonol 3,4-dihydroxyflavonol (DiOHF) inhibits platelet function and delays thrombus formation in healthy mice. Therefore, the aim of this study was to investigate the effect of Que or DiOHF treatment on platelet function and ferric chloride-induced carotid artery thrombosis in a mouse model of type 1 diabetes. Diabetic mice treated with Que or DiOHF maintained blood flow at a significantly higher level than untreated diabetic mice at the end of the recording period. In addition, treatment with Que or DiOHF significantly reduced diabetes-induced platelet hyper-aggregability in response to platelet agonist stimulation. Furthermore, treatment with Que or DiOHF significantly inhibited dense, but not alpha, granule exocytosis in diabetic and control mice. Our demonstration that flavonols delay thrombus formation in diabetes suggests a potential clinical role for these compounds in anti-platelet therapy. © The Author(s) 2014.

AB - Diabetes is associated with increased cardiovascular risk. We have recently shown that the naturally occurring flavonol quercetin (Que) or the synthetic flavonol 3,4-dihydroxyflavonol (DiOHF) inhibits platelet function and delays thrombus formation in healthy mice. Therefore, the aim of this study was to investigate the effect of Que or DiOHF treatment on platelet function and ferric chloride-induced carotid artery thrombosis in a mouse model of type 1 diabetes. Diabetic mice treated with Que or DiOHF maintained blood flow at a significantly higher level than untreated diabetic mice at the end of the recording period. In addition, treatment with Que or DiOHF significantly reduced diabetes-induced platelet hyper-aggregability in response to platelet agonist stimulation. Furthermore, treatment with Que or DiOHF significantly inhibited dense, but not alpha, granule exocytosis in diabetic and control mice. Our demonstration that flavonols delay thrombus formation in diabetes suggests a potential clinical role for these compounds in anti-platelet therapy. © The Author(s) 2014.

U2 - 10.1177/1479164114524234

DO - 10.1177/1479164114524234

M3 - Article

VL - 11

SP - 174

EP - 181

JO - DIABETES & VASCULAR DISEASE RESEARCH

JF - DIABETES & VASCULAR DISEASE RESEARCH

SN - 1479-1641

IS - 3

ER -